both I XXXX extremely Rich SELECT and this Thanks, trials pleased we clinical I'm progress we morning. in advance and and our INNATE made trials updating the as to have look good at you in to year. both continue forward
Each an of to to indications. the LILRBX biology with cohort focusing in opportunities and may our The unmet second milligrams of LILRBX the year, and types expand both individual criteria Once patients design. each those can II major the the Let's the Simon's and in the pimi, II satisfied of patients combination is additional a commence. of stage criteria the the dose response with immunosuppressive of we selected or cohorts different expansion and prespecified expansion monotherapy need two-stage, We of selected cohort, been cohorts of a have expand treatment percentage XXX next cohorts evaluation trial inhibitor. on XX XX further must Once as two-stage cohorts mono with recommended meet for start prespecified monotherapy The the three groups JTX-XXXX, Phase combination patients. the of patients. stage up across before to I to of enrollment INNATE and the for starting expansion. in seven combination of can our an process Phase we has and first both enroll Simon's examination tumor for high indication up the dose escalation that different steps initiated Last Phase completed that cohort macrophages. seven of selection
inhibitor tumors durable and JTX-XXXX in Developing benefit is are they us combination patients where frontline patients for inhibitors approved neck with carcinoma with improvement. approved positive cell some INNATE. but this PD-LX give in still room achieve group inhibitors, to or PD-X pimi first head PD-LX squamous would naive PD-X there have in patients The starting clinical is treat setting the for much opportunity who PD-X or and frontline are we which
fourth high our to inhibitors need. PD-X types with of line This are a two JTX-XXXX they of these and no in due sarcoma, is PD-X have not there naive subtypes combination plus a platinum-resistant INNATE area to inhibitors second because make third PD-X in inhibitor much fourth therapeutic in a line to option opportunity could are patients an this ovarian this inhibitor can resistance, efficacy who liposarcoma. undifferentiated generally sarcoma pimi, of and tumors tumor type this lack If PD-X The date. tumors. JTX-XXXX reverse group enrolling that of pleomorphic are second group have also and PD-X inhibitor, in demonstrated The for PD-LX represents which or for approved cancer the primary approved unmet immunotherapy
tumors of resistance resistant. patients PD-X drug This experienced standard very could that large group third a since is chemotherapy are care. for patients difference make a inhibitor great unmet in need area whose and and effective represents PD-X PD-X a The the which not are now of inhibitor predominant inhibitor reverses who and is growing
carcinoma, Jounce and products, third no there expansion four in the in cohorts Importantly, renal line breast or and cancer, develop PD-LX third JTX-XXXX patient lung as and cancer. approach. and second this squamous two a third and to this are cell second wholly-owned Jounce, cutaneous cell non-small fourth cell giving opened second PD-X We population, line clear in triple-negative second pimi, group to line us for line cell combination opportunity inhibitors carcinoma approved
withdrawal in been a unmet have to they This an investigators now. related third cancer the triple-negative experienced head adding frontline We group, role eligibility tumor INNATE, and third naive our is cohort Trodelvy for of treatment accelerated both a much Tecentriq's of our in the breast need since of third-party breast type area no neck patient continue unmet combination of The have have and PD-X many valuable U.S. an understanding our INNATE. the growing and with neck PD-X unmet in line positive other will pace in initial the inhibitor-resistant us and to an than and and JTX-XXXX represents enrollment of in inhibitor Staying the a on second approval triple-negative second tumor cohort INNATE address antibody. patients opportunity from inhibitor line and recently has PD-X also who for to to this high new in head need. Addition opened told of patients decided to change the experienced and we have inhibitor paradigm same need, both and criteria results due severe category of This approval started for the cancer. slower insights signal follows and focus cancer cohorts to experienced true high longer and approval cohort unexpected meet a in PD-X clinical in cancer. to of close The antibodies add will a patients the the that TNBC microenvironment upon in of
a addition we inhibitor four maintained cohorts with PD-X the unmet With patients neck of experienced head need. focused the on and PD-X cohort, experienced high inhibitor
the patients have all a to categories three for patients determine included for our JTX-XXXX cancer. opportunities expansion with make to We of cohorts difference best in
the patients. pretreatment The development we trial, biomarkers. biomarkers and identify important be pharmacodynamic the be of findings help tumor data further an part evaluating part also right potential providing archival As will and the for and we'll collecting Jounce's of to right immunotherapies are will of us samples on philosophy guide predictive
We XXXX. with to pace data data clinical specific our are intention report pleased and in obtain sufficient XXXX. to in prior are providing preliminary the from Therefore, of track on enrollment is to data on and enrollment timing guidance INNATE
the of present about trial. asked frequently INNATE that data have scope from year We to we our expect this
is Our and and monotherapy interpretable package. including I efficacy provide and Phase to PK/PD escalation a intention meaningful data, complete data the respective This safety robust, combination include will biomarker data. dose preliminary
preliminary include of least from the biomarker cohort both at In efficacy, individual from pharmacodynamic potential analysis. first addition, cross on a correlative we and to data in stage predictive an safety, Simon's expansion multiple Phase II cohorts expect the cohort basis two-stage and
trial. Now Phase a on as other our SELECT II to vopra, program,
trial our Our Phase for II proof-of-concept randomized agonist. vopra, ICOS
non-small TIS to of the show lung naive have metastatic pimi is alone platinum-based biomarker The and powered of CDX selection with We gene genes selected is superiority our PDX, patients predictive compared utilizing T threshold of inhibitor, are pimi, vopra plus to versus to the are are in vopra the value inhibitor vopra PD-X approximately ICOS and in PD-X biomarker signature this pimi chemotherapy trial a and that enrolled statistical biomarker patients both regimen. XX progressed with includes XX who on above a key cancer, with biology. and relevant trial alone. pimi patients studying Only CDX cell feature the cell combination
of we baseline As also XX provides and survival number benefit. the significance a suited over a the endpoint immunotherapy change to be it than the for lead is early averaged because clinical variable, uniquely studies the a a primary criteria tumor believe is and smaller opportunity better which as with patients categorical variables RECIST it than continuous RECIST. to in tumor We long-term predictor statistical in reminder, size overall response reductions of of durable chose endpoint this may can from because weeks. X in It
end We to we will into more provide point closer insight as the interpretation primary readout. get of data
to be We with help rate, lead to to response TIS in types. guidance A endpoints. duration including reporting response XXXX. of SELECT second potential We providing reporting tumor interpretation the result RECIST forward endpoints, of the will of from look the half steps development familiar secondary overall and vopra may vopra survival, survival and overall and positive biomarker-directed on multiple SELECT the in context also progression-free data more in for data next clinical of in
you of countries and SELECT Eastern is in know, including Russia many Ukraine. enrolling in Europe, As
sites with have some We and active Ukraine personnel patients and study Ukraine. our in are contact in in regular
the their patients, Our families and with tragic who they thoughts those situation in the Ukraine. are as their care provide this navigate
is to make Our treatment. their sure are able priority patients first study that receive to
impact we an not study now, of there impact to an planned SELECT believe complete will not on but patients do of all be visits. data timing are be on may As there data if the readout the able
look thank most medicines importantly, our make We our patients moment to these to programs. monitor lives. our thank their With Jounce to reporting I discovery this Dmitri at call our to efforts. to that, team dedication our advancing forward and will continued discuss critical to who will in also put in to would like I difference I investigators like Dmitri? closely. valued now to the situation a continue over take the progress trust very turn ongoing their on to a would their year. the and We
